Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCT Biomarkers for Ublituximab Response in MS
NCT06864936Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of ublituximab in multiple sclerosis (MS) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Macular hyperreflective foci at 12 months and Inner limiting membrane macrophage-like cells at 12 months. Started May 2026; status: recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06864936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864936.